The company that produces high-quality and innovative life science ingredients catering to pharmaceuticals, nutrition, agrochemicals, consumer goods, and industrial applications gained 4.8 percent after the company commissioned a new manufacturing facility for diketene derivatives.
On Monday’s second half of trade, at 3:25 p.m., Jubilant Ingrevia Ltd shares were trading at ₹469 per share, up 3.68 percent on the National Stock Exchange. The company has a market capitalization of ₹7,476 crore.
According to the company’s official filing, Jubilant Ingrevia Ltd has commissioned a new facility at its manufacturing site in Gajraula, Uttar Pradesh, for the production of Diketene derivatives.
Currently, the company possesses a portfolio of more than 134 commercialized products and innovative solutions across 35 essential chemistry and technology platforms spanning its Specialty, Nutrition, and Chemical intermediates divisions.
This latest facility expansion will increase the company’s production capacity by 2,000 metric tons per annum (TPA) to cater to the demand for high-value esters.
Jubilant Ingrevia, is a globally integrated Life Science products and Innovative Solutions provider serving pharmaceutical, nutrition, Nutrition, Agrochemical, Consumer, and Industrial customers.
The company serves over 1,600 clients spanning more than 50 countries globally. Furthermore, it has outlined a capex plan amounting to ₹2,000 Crore until the fiscal year 2025.
Ace investor Rekha Jhunjhunwala currently possesses a 3.12 percent stake in the company as of December 2023, which translates to ownership of 49,65,000 equity shares.
Jubilant Ingrevia Ltd witnessed a 17 percent annual decline in revenue, dropping from ₹1,158 crore in Q3FY23 to ₹966 crore in Q3FY24. Simultaneously, its net profit plummeted by 57 percent from ₹92 crore to ₹39 crore during the same period.
Over the past 12 months, shares of Jubilant Ingrevia Ltd have appreciated by 26 percent, although they experienced a 2.3 percent decline in the last six months.
Written by Omkar Chitnis
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
